Skip to main content

PAPEL DE SIRT2 MICROGLIAL EN LA ENFERMEDAD DE ALZHEIMER

PID2020-119729GB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2020
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD DE NAVARRA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

SIRT2 Inhibition Rescues Neurodegenerative Pathology but Increases Systemic Inflammation in a Transgenic Mouse Model of Alzheimer’s Disease

  • Sola-Sevilla, N.
  • Mesa-Lombardo, A.
  • Aleixo, M.
  • Expósito, Sara
  • Diaz-Perdigón, T.
  • Azqueta, Amaya
  • Zamani, F.
  • Suzuki, T.
  • Maioli, Silvia
  • Eroli, F.
  • Matton, A.
  • Ramírez, M. José
  • Solas, Maite
  • Tordera, R. M.
  • Martín, E. D.
  • Puerta, E.
Sirtuin 2 (SIRT2) has been proposed to have a central role on aging, inflammation, cancer and neurodegenerative diseases; however, its specific function remains controversial. Recent studies propose SIRT2 pharmacological inhibition as a therapeutic strategy for several neurodegenerative diseases including Alzheimer’s disease (AD). Surprisingly, none of these published studies regarding the potential interest of SIRT2 inhibition has assessed the peripheral adverse side consequences of this treatment. In this study, we demonstrate that the specific SIRT2 inhibitor, the compound 33i, does not exhibit genotoxic or mutagenic properties. Moreover, pharmacological treatment with 33i, improved cognitive dysfunction and long-term potentiation, reducing amyloid pathology and neuroinflammation in the APP/PS1 AD mouse model. However, this treatment increased peripheral levels of the inflammatory cytokines IL-1β, TNF, IL-6 and MCP-1. Accordingly, peripheral SIRT2 inhibition with the blood brain barrier impermeable compound AGK-2, worsened the cognitive capacities and increased systemic inflammation. The analysis of human samples revealed that SIRT2 is increased in the brain but not in the serum of AD patients. These results suggest that, although SIRT2 pharmacological inhibition may have beneficial consequences in neurodegenerative diseases, its pharmacological inhibition at the periphery would not be recommended and the systemic adverse side effects should be considered. This information is essential to maximize the therapeutic potential of SIRT2 inhibition not only for AD but also for other neurodegenerative diseases. Graphical Abstract: [Figure not available: see fulltext.], Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This research was funded by FEDER/Ministerio de Ciencia, Innovación y Universidades Agencia Estatal de Investigación/ Project (SAF2017-87595-R and PID2020-119729 GB-100)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

SIRT2 Inhibition Rescues Neurodegenerative Pathology but Increases Systemic Inflammation in a Transgenic Mouse Model of Alzheimer’s Disease

  • Sola-Sevilla, N.
  • Mesa-Lombardo, A.
  • Aleixo, M.
  • Expósito, Sara
  • Diaz-Perdigón, T.
  • Azqueta, Amaya
  • Zamani, F.
  • Suzuki, T.
  • Maioli, Silvia
  • Eroli, F.
  • Matton, A.
  • Ramírez, M. José
  • Solas, Maite
  • Tordera, R.M.
  • Martín, E.D.
  • Puerta, E.
Sirtuin 2 (SIRT2) has been proposed to have a central role on aging, inflammation, cancer and neurodegenerative diseases; however, its specific function remains controversial. Recent studies propose SIRT2 pharmacological inhibition as a therapeutic strategy for several neurodegenerative diseases including Alzheimer’s disease (AD). Surprisingly, none of these published studies regarding the potential interest of SIRT2 inhibition has assessed the peripheral adverse side consequences of this treatment. In this study, we demonstrate that the specific SIRT2 inhibitor, the compound 33i, does not exhibit genotoxic or mutagenic properties. Moreover, pharmacological treatment with 33i, improved cognitive dysfunction and long-term potentiation, reducing amyloid pathology and neuroinflammation in the APP/PS1 AD mouse model. However, this treatment increased peripheral levels of the inflammatory cytokines IL-1β, TNF, IL-6 and MCP-1. Accordingly, peripheral SIRT2 inhibition with the blood brain barrier impermeable compound AGK-2, worsened the cognitive capacities and increased systemic inflammation. The analysis of human samples revealed that SIRT2 is increased in the brain but not in the serum of AD patients. These results suggest that, although SIRT2 pharmacological inhibition may have beneficial consequences in neurodegenerative diseases, its pharmacological inhibition at the periphery would not be recommended and the systemic adverse side effects should be considered. This information is essential to maximize the therapeutic potential of SIRT2 inhibition not only for AD but also for other neurodegenerative diseases. Graphical Abstract: [Figure not available: see fulltext.], Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This research was funded by FEDER/Ministerio de Ciencia, Innovación y Universidades Agencia Estatal de Investigación/ Project (SAF2017-87595-R and PID2020-119729 GB-100).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Microglial SIRT2 deficiency aggravates cognitive decline and amyloid pathology in Alzheimer's disease

  • Sola-Sevilla, Noemi
  • Garmendia-Berges, Maider
  • Aleixo, Mikel
  • Mera-Delgado, MCarmen
  • Solas, Maite
  • Tordera, Rosa M
  • García-Carracedo, Lucía
  • Expósito, Sara
  • Anaya-Cubero, Elena
  • Fernández-Irigoyen, Joaquín
  • Guruceaga, Elisabeth
  • Santamaria, Enrique
  • Martin, Eduardo D
  • Puerta, Elena
Sirtuin 2 (SIRT2), a NAD+-dependent deacetylase, has been implicated in aging and neurodegenerative diseases such as Alzheimer's disease (AD). While global SIRT2 inhibition has shown promise in reducing amyloid-beta pathology and cognitive deficits in different mouse models of AD, peripheral SIRT2 inhibition has been associated with adverse effects, such as increased inflammation. This suggests that targeted inhibition of specific cellular populations within the brain may represent a more precise and effective approach for the treatment of AD. To explore this hypothesis, we generated a conditional microglial SIRT2 knockout mouse model in the context of AD. Our results reveal that microglial SIRT2 reduction does not confer protective effects in the APP/PS1 model; rather, it aggravates cognitive decline, accelerates amyloid plaque deposition, and increases levels of pro-inflammatory cytokines at early stages of AD pathology. Transcriptomic analysis further indicates that SIRT2-deficient microglia exhibit altered expression of genes associated with aging and synaptic dysfunction. This phenotype was accompanied by increased phagocytosis of PSD95 and impaired long-term potentiation. These findings suggest that while SIRT2 inhibition in some contexts may be beneficial, targeted inhibition within microglia could accelerate AD progression, underscoring the need for cell-specific approaches when considering SIRT2 as a therapeutic target., This work was supported by grant PID2020-119729GB-I00 funded by MICIU/AEI/ 10.13039/501100011033 to EP and partially by grant PID2023-152593OB-I00 funded by 501100011033 / FEDER, UE to ES and JFI., Peer reviewed
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Microglial SIRT2 deficiency aggravates cognitive decline and amyloid pathology in Alzheimer's disease

  • Sola-Sevilla, Noemi
  • Garmendia-Berges, Maider
  • Aleixo, Mikel
  • Mera-Delgado, Mª Carmen
  • Solas, Maite
  • Tordera, Rosa M.
  • García-Carracedo, Lucía
  • Expósito, Sara
  • Anaya-Cubero, Elena
  • Fernández Irigoyen, Joaquín
  • Guruceaga, Elizabeth
  • Santamaría Martínez, Enrique
  • Martín, Eduardo D.
  • Puerta, Elena
Sirtuin 2 (SIRT2), a NAD+-dependent deacetylase, has been implicated in aging and neurodegenerative diseases such as Alzheimer's disease (AD). While global SIRT2 inhibition has shown promise in reducing amyloid-beta pathology and cognitive deficits in different mouse models of AD, peripheral SIRT2 inhibition has been associated with adverse effects, such as increased inflammation. This suggests that targeted inhibition of specific cellular populations within the brain may represent a more precise and effective approach for the treatment of AD. To explore this hypothesis, we generated a conditional microglial SIRT2 knockout mouse model in the context of AD. Our results reveal that microglial SIRT2 reduction does not confer protective effects in the APP/PS1 model; rather, it aggravates cognitive decline, accelerates amyloid plaque deposition, and increases levels of pro-inflammatory cytokines at early stages of AD pathology. Transcriptomic analysis further indicates that SIRT2-deficient microglia exhibit altered expression of genes associated with aging and synaptic dysfunction. This phenotype was accompanied by increased phagocytosis of PSD95 and impaired long-term potentiation. These findings suggest that while SIRT2 inhibition in some contexts may be beneficial, targeted inhibition within microglia could accelerate AD progression, underscoring the need for cell-specific approaches when considering SIRT2 as a therapeutic target., This work was supported by grant PID2020-119729GB-I00 funded by MICIU/AEI/ 10.13039/501100011033 to EP and partially by grant PID2023-152593OB-I00 funded by MCIU/AEI/ 10.13039/ 501100011033 / FEDER, UE to ES and JFI.